At the time of enrollment a relatively low number of CAD-REF patients were treated with cardioprotective drugs such as ACE inhibitors or ARBs, beta-blockers, statins and platelet inhibitors as also found in other reports [14,15,27,30,31,]. This evidence concerns the gene ACE and coronary artery disorder.